Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
The Lancet Diabetes and Endocrinology is Scopus-indexed (Q1, CiteScore 64.1), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Elsevier Ltd.
Checked against the index lists dated .
ISSN 2213-8587Verify ISSN ↗2213-8595Verify ISSN ↗
Publisher: Elsevier Ltd
Cost to publish: About US$7,280 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Endocrinology, Diabetes and Metabolism | 1 / 250 | 99th | Q1 |
| Internal Medicine | 1 / 179 | 99th | Q1 |
| Endocrinology | 1 / 132 | 99th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2013–present, best quartile Q1, CiteScore 64.1.
The Lancet Diabetes and Endocrinology is Q1 in Endocrinology, Diabetes and Metabolism (rank 1 of 250), Q1 in Internal Medicine (rank 1 of 179) and Q1 in Endocrinology (rank 1 of 132), by CiteScore 2025.
The Lancet Diabetes and Endocrinology is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 64.1, which places it in quartile Q1 at the 99th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 11.610, quartile Q1, with an H-index of 207.
The publisher lists an article processing charge of about US$7,280 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
The Lancet Diabetes and Endocrinology is published by Elsevier Ltd. Its print ISSN is 2213-8587 and its online ISSN is 2213-8595.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
The Lancet Diabetes and Endocrinology has an h-index of 251 and a 2-year mean of 17.31 citations per paper (OpenAlex). Its Scopus CiteScore is 64.1, quartile Q1. On 2-year citations it ranks #4 of 246 Scopus journals in Endocrinology, Diabetes and Metabolism.
The Lancet Diabetes and Endocrinology published 220 papers in 2025; its busiest recent year was 2017 with 250. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 86 research articles (2026), authors are most often from United Kingdom (19.8%), United States (17.7%) and Denmark (5.8%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 12 retracted papers are recorded (3.8 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.